Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compounds or agents that inhibit and induce the formation of focal microvessel dilatations

a microvessel and focal microvessel technology, applied in the field of inflammation modulation, can solve the problems of no conception of the potential use of pro-angiogenic factors in cancer treatment, and achieve the effects of broadening the potential for development of therapeutics, promoting lymphocyte transmigration, and preventing pathologies involving lymphocytic inflammation

Inactive Publication Date: 2005-06-30
DANA FARBER CANCER INST INC
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new method for screening compounds that can inhibit the formation of small blood vessel dilatations (focal microvessel dilatations) in the microcirculation. These dilatations are associated with a proliferative and remodeled endothelium, and can be induced by pro-angiogenic factors. The patent also describes a method for treating cancer and inflammatory disorders by inducing the formation of focal microvessel dilatations to promote lymphocyte transmigration and tumor cell death. The patent also discusses the use of pro-angiogenic factors to induce the formation of focal microvessel dilatations, and the combination therapy of anti-angiogenic compounds and anti-adhesion compounds for the treatment of lymphocytic inflammation.

Problems solved by technology

However, until now, there has been no conception for the potential use of pro-angiogenic factors in the treatment of cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds or agents that inhibit and induce the formation of focal microvessel dilatations
  • Compounds or agents that inhibit and induce the formation of focal microvessel dilatations
  • Compounds or agents that inhibit and induce the formation of focal microvessel dilatations

Examples

Experimental program
Comparison scheme
Effect test

example 1

Lymphocyte Slowing and Transmigration in Focal Microvessel Dilatations

[0121] The intravital videomicroscopy studies demonstrated reproducible lymphocyte slowing in focal regions of the microcirculation (FIG. 1). Lymphocytes in these regions demonstrated a greater than 10-fold reduction in flow velocity (FIGS. 2 and 3). After the cells passed through these vascular segments, they rapidly returned to baseline flow velocities (FIG. 4). Also suggesting discrete structural changes in the sheep skin microcirculation, the regions of lymphocyte slowing were identified at approximately 100 um intervals (FIG. 1). The focal areas defined not only areas of lymphocyte slowing, but also the regions of lymphocyte transmigration. The focal areas of lymphocyte slowing were the only regions of the superficial vascular plexus where lymphocyte transmigration was observed (FIG. 1) (West et al. (2001), Am. J. Physiol. Heart Circ. 281, H1742-H1750. These findings suggested that lymphocyte transmigration ...

example 2

Focal Microvessel Dilatation Morphology

[0122] To evaluate the morphology of these focal regions of lymphocyte slowing and transmigration, corrosion cast injections of the inflammatory microcirculation were performed. The corrosion casts were examined by scanning and transmission electron microscopy and evaluated by digital morphometry. After systemic heparinization with 750 u / kg intravenous heparin, the external auricular arteries were bilaterally cannulated and perfused with approximately 100 cc of 37° C. saline followed by a 2.5 percent buffered glutaraldehyde solution (Sigma) at pH 7.40. The casts were made by perfusion of the ear arteries with 100 cc of Mercox (SPI, West Chester Pa.) diluted with 20 percent methylmethacrylate monomers (Aldrich Chemical, Milwaukee Wis.). After complete polymerization, the ears were harvested and macerated in 5% potassium hydroxide followed by drying and mounting for scanning electron microscopy. The microvascular corrosion casts were imaged afte...

example 3

Focal Microvessel Dilatation Wall Shear Stress and Microhemodynamic Mapping of Focal Microvessel Dilatations

[0124] The focal structural changes and the reduction in flow velocity indicated that focal microvessel dilatations have a significant impact on wall shear stress in the microcirculation. To define the microhemodynamic implications of the focal microvessel dilatations, the corrosion casts of the inflammatory skin were evaluated by quantitative 3-dimensional (3-D) scanning electron microscopy (Konerding, et al. (2001), Br J Cancer 84, 1354-62, M. A. Konerding et al. (1999), Br J Cancer 80, 724-32). Based on these data, 3-D hemodynamic maps of the focal microvessel dilatations were calculated. Wall shear stresses in the focal microvessel dilatations demonstrated a greater than 10-fold reduction in wall shear stress (FIG. 6). To estimate wall shear stresses, finite-element computations of flow fields in the neighborhood of the transition from the afferent vessel to the dilated s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the discovery that inflammation involves a structural modification to the microvascular architecture that results in the formation of focal microvessel dilatations or “microangiectasias.” The focal microvessel dilatations cause localized slowing of blood cell flow velocity that promotes the accumulation of extravascular lymphocytes. Methods are disclosed herein that exploit this discovery to screen for compounds that modulate the accumulation of extravascular lymphocytes. In addition, methods for treating patients suffering from cancer and diseases or pathologies associated with lymphocytic infiltration are disclosed.

Description

RELATED APPLICATIONS [0001] This application is a Continuation of PCT / US03 / 17790, filed Jun. 6, 2003, which claimed priority to U.S. Provisional Application No. 60 / 386,831, filed Jun. 6, 2002; the entirety of each of which is incorporated herein by reference.GOVERNMENT GRANTS [0002] At least part of the work contained in this application was performed under NIH grant HL47078. The government may have certain rights in this invention.FIELD OF THE INVENTION [0003] This invention relates to the modulation of inflammation. BACKGROUND OF THE INVENTION [0004] When recirculating lymphocytes migrate from the microcirculation to the extravascular site of inflammation, they must overcome the mechanical forces produced by blood flow. Blood flowing across the vascular endothelium creates shear forces at the endothelial boundary that are dependent on both flow velocity and vessel geometry. These shear forces disrupt the lymphocyte-endothelial cell adhesions necessary for transmigration. For more ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K49/00
CPCA61K49/0004
Inventor MENTZER, STEVEN J.
Owner DANA FARBER CANCER INST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products